عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
TT
TT

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.
The drug, datopotamab deruxtecan, which AstraZeneca is jointly developing with Japan's Daiichi Sankyo, is being closely watched by analysts and investors in part due to the promise of the class of drugs to which it belongs, known as antibody drug conjugates (ADC).
ADCs consist of tumor-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
The trial data released on Friday showed the drug, abbreviated as Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in slowing the progression of a type of breast cancer in trial participants, compared to patients who received other treatments such as chemotherapy.
The trial focused on tumors that grow in response to the hormones estrogen or progesterone, which account for roughly two-thirds of breast cancer cases. The study participants' disease had spread to other parts of the body.
The British drugmaker also said that there was a "trend in improvement" in the other main goal of the study, "overall survival" of patients, but the data on that was not mature so the trial would continue as planned.
AstraZeneca shares rose 1.7% in early trading, to their highest level in more than five weeks.
AstraZeneca is simultaneously developing the drug for use in lung cancer, and while data from a separate late-stage trial released in July was positive, the market was concerned that the drug's benefits for use in lung cancer treatment might not as pronounced as hoped, leading shares to fall more than 6% on the day the data was released.
The company has not said when it will release detailed data from the lung cancer study.
Analysts see the positive results from the breast cancer trial as good for AstraZeneca, but the market is more focused on the results of a trial called MARIPOSA by Johnson & Johnson. It compares AstraZeneca’s blockbuster cancer drug Tagrisso alone with its own drug, Rybrevant, in combination with another medicine.
Those results are expected later this year.

Most Viewed

 
 
Varieties

Beirut's 'Mother of Cats' Who Rescues Felines

Diana Abadi, known as "the mother of cats," sits with felines waiting for adoption at her small pet food and plant shop in Hadath, in Beirut's southern suburbs known as Dahiyeh, in Lebanon, Saturday, Feb. 7, 2026. (AP Photo/Bilal Hussein)
Diana Abadi, known as "the mother of cats," sits with felines waiting for adoption at her small pet food and plant shop in Hadath, in Beirut's southern suburbs known as Dahiyeh, in Lebanon, Saturday, Feb. 7, 2026. (AP Photo/Bilal Hussein)
TT
TT

Beirut's 'Mother of Cats' Who Rescues Felines

Diana Abadi, known as "the mother of cats," sits with felines waiting for adoption at her small pet food and plant shop in Hadath, in Beirut's southern suburbs known as Dahiyeh, in Lebanon, Saturday, Feb. 7, 2026. (AP Photo/Bilal Hussein)
Diana Abadi, known as "the mother of cats," sits with felines waiting for adoption at her small pet food and plant shop in Hadath, in Beirut's southern suburbs known as Dahiyeh, in Lebanon, Saturday, Feb. 7, 2026. (AP Photo/Bilal Hussein)

Diana Abadi is known in the southern suburbs of Beirut as the “Mother of Cats.”

For the past 12 years, she has turned her home and shop into a refuge for abandoned felines who now number between 50 and 70, and she often sleeps beside the cats as she cares for them full time.

Abadi began by taking in a single kitten.

Word spread, and residents started bringing her injured and unwanted animals, especially during periods of crisis. At its peak, the shelter housed more than 150 cats, especially during the COVID-19 pandemic and the recent Israel-Hezbollah war, when fear and displacement led many people to abandon their pets.

Her plant and pet food shop in the southern suburbs known as Dahiyeh serves as both her livelihood and the cats’ shelter. Among those currently in her care are Joujou, 13, the oldest, as well as cats named Loulou, Fluffy, Emma and Panda.

One of the most challenging cases involves a cat that was completely blind when abandoned. A woman offered to cover the animal’s expenses if Abadi would take him in. After months of treatment, the cat has partially regained vision in one eye.

Social media has recently helped improve adoption rates, reducing the number of cats under Abadi's care. Rising costs, however, threaten the shelter’s future. Monthly rent has climbed to $800, up from $250 before the war, forcing Abadi to cover most expenses herself.

“These are living beings,” she said. “I don’t take holidays or Sundays off.”

Varieties

Face of 400-Year-Old 'Vampire' Recreated

Scientists have given a face to a decapitated skull which was uncovered in Croatia. (Croatia’s excavation team)
Scientists have given a face to a decapitated skull which was uncovered in Croatia. (Croatia’s excavation team)
TT
TT

Face of 400-Year-Old 'Vampire' Recreated

Scientists have given a face to a decapitated skull which was uncovered in Croatia. (Croatia’s excavation team)
Scientists have given a face to a decapitated skull which was uncovered in Croatia. (Croatia’s excavation team)

The face of a "vampire", whose remains were posthumously mutilated to prevent them from rising from the dead, can be seen for the first time in more than 400 years, reported Sky News.

Discovered in a grave at Racesa, a fortress in eastern Croatia, the body had been exhumed, beheaded and reburied face down beneath heavy stones.

And since the desecration cannot be explained by environmental factors, experts believe it was done to stop the dead man returning as a vampire.

Now the face of the deceased can be seen for the first time in centuries, after scientists rebuilt his likeness from his skull.

Archaeologist Natasa Sarkic, part of the excavation team, said the fear inspired by the man in death may stem from the fear he inspired in life.

She said: “Bioarchaeological analysis showed that this man often participated in violent conflicts, and died a violent death. He experienced at least three episodes of serious interpersonal violence during his lifetime.”

“One of those attacks left his face disfigured, which could cause fear and repulsion, leading to social exclusion. Before even recovering from the penultimate trauma, he sustained a final fatal attack,” she revealed.

“Individuals who died violently, behaved violently in life, or were considered sinful or socially deviant, were believed to be at risk of becoming vampires,” she continued.

“He may have been regarded as a 'vampire', or a supernatural threat due to his facial disfigurement and his marginal lifestyle, characterized by repeated interpersonal violence,” Sarkic explained.

She said such beings were thought to be restless, vengeful, and capable of harming the living, spreading disease and killing people or livestock.

Sarkic said that, in the Slavic tradition, the soul remains attached to the body for about 40 days after death.

Varieties

Caffeinated Beverages May Help Protect the Brain, Study Says

A cup of coffee and a cappuccino are seen at a Juan Valdez store in Bogota, Colombia June 5, 2019. (Reuters)
A cup of coffee and a cappuccino are seen at a Juan Valdez store in Bogota, Colombia June 5, 2019. (Reuters)
TT
TT

Caffeinated Beverages May Help Protect the Brain, Study Says

A cup of coffee and a cappuccino are seen at a Juan Valdez store in Bogota, Colombia June 5, 2019. (Reuters)
A cup of coffee and a cappuccino are seen at a Juan Valdez store in Bogota, Colombia June 5, 2019. (Reuters)

Drinking a few cups of caffeinated coffee or tea every day may help in a small way to preserve brain power and prevent dementia, researchers reported on Monday.

People with the highest daily intake of caffeinated coffee had an 18% lower risk of developing dementia compared to those with the lowest such intake, according to a study based on responses to questionnaires by 132,000 U.S. adults spanning four decades.

The study, published in JAMA, also found that the people with the highest intake had a lower rate - by nearly 2 percentage points - of ‌self-perceived memory ‌or thinking problems compared to those with ‌the ⁠lowest intake.

Results were ‌similar with caffeinated tea, but not with decaffeinated beverages, the researchers said.

While the findings are encouraging, the study does not prove caffeine helps protect the brain, they said.

The magnitude of caffeine's effect, if any, was small, and there are other better-documented ways to protect cognitive function as people age, study leader Dr. Daniel Wang ⁠of Harvard Medical School said in a statement.

Lifestyle factors linked with lower risks of ‌dementia include physical exercise, a healthy diet ‍and adequate sleep, according to previous ‍research.

"Our study suggests that caffeinated coffee or tea consumption can ‍be one piece of that puzzle," Wang said.

The findings were most pronounced in participants who consumed two to three cups of caffeinated coffee or one to two cups of caffeinated tea daily, the researchers reported.

Those who drank caffeinated coffee also showed better performance on some objective tests of cognitive function, according to the ⁠study funded by the National Institutes of Health.

Further research is needed to validate the factors and mechanisms responsible for the findings, the researchers said.

They noted that bioactive ingredients in coffee and tea such as caffeine and polyphenols have emerged as possible factors that reduce nerve cell inflammation and damage while protecting against cognitive decline.

"We also compared people with different genetic predispositions to developing dementia and saw the same results - meaning coffee or caffeine is likely equally beneficial for people with high and low genetic risk of developing ‌dementia," study coauthor Dr. Yu Zhang of the Harvard T.H. Chan School of Public Health said in a statement.